Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm

Cancer Family

Malignant Neoplasm

CI-CAN-00000025CAExplore in graph →

20,116 active trials259 approved drugs3,741 evidence items

NCIt: C9305
OncoTree: MT
DOID: 162
UMLS CUI: C0006826

Overview
Statistics
Survival
Genomics442
Variants & evidence3741
Drugs424
Trials90685
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,349)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,976–4,000 of 4,349 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
· Nat Commun · 2025 · PMID 40169546 · validated civic_curation pubmed
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.
· NPJ Precis Oncol · 2021 · PMID 34272467 · validated civic_curation pubmed
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
· PLoS One · 2007 · PMID 17726540 · validated civic_curation pubmed
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
· Cancer Cell · 2007 · PMID 18068628 · validated civic_curation pubmed
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
· Mol Cancer · 2014 · PMID 24735930 · validated civic_curation pubmed
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
· Mol Cancer Ther · 2015 · PMID 25398829 · validated civic_curation pubmed
Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
· Tumour Biol · 2016 · PMID 26596839 · validated civic_curation

Showing 3,976–4,000 of 4,349 publications

← Previous
1
…
159
160
161
…
174
Next →

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

· Int J Cancer · 2016 · PMID 26686064 · validated civic_curation pubmed

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

· Autophagy · 2015 · PMID 26391455 · validated civic_curation pubmed

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

· Mol Cancer Ther · 2015 · PMID 25939761 · validated civic_curation pubmed

Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.

· Anticancer Res · 2015 · PMID 26637881 · validated civic_curation pubmed

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

· Oncotarget · 2015 · PMID 25883215 · validated civic_curation pubmed

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.

· Oncogene · 2016 · PMID 25982282 · validated civic_curation pubmed

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

· Oncotarget · 2014 · PMID 25153719 · validated civic_curation pubmed

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.

· Anticancer Drugs · 2014 · PMID 25089570 · validated civic_curation pubmed

Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

· PLoS One · 2014 · PMID 24927325 · validated civic_curation pubmed

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.

· Anticancer Res · 2015 · PMID 25862853 · validated civic_curation pubmed

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

· Digestion · 2013 · PMID 24135816 · validated civic_curation pubmed

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

· Tumour Biol · 2013 · PMID 23881388 · validated civic_curation pubmed

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

· Cell Oncol (Dordr) · 2013 · PMID 23619944 · validated civic_curation pubmed

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

· Cancer Lett · 2013 · PMID 23340172 · validated civic_curation pubmed

Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.

· Oncotarget · 2011 · PMID 21576762 · validated civic_curation pubmed

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.

· Br J Cancer · 2012 · PMID 22343617 · validated civic_curation pubmed

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

· Cell Cycle · 2012 · PMID 22262166 · validated civic_curation pubmed

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

· J Pathol · 2012 · PMID 22190288 · validated civic_curation pubmed